Novartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum
BioTech Gate,
Cosentyx ® is the first fully-human IL-17A inhibitor indicated for patients in Europe with non-radiographic axial…
Cosentyx ® is the first fully-human IL-17A inhibitor indicated for patients in Europe with non-radiographic axial…
Cosentyx ® is the first fully-human IL-17A inhibitor indicated for patients in Europe with non-radiographic axial…
— Novartis, a leader in rheumatology and immuno-dermatology, today announced the European Commission (EC) has approved Cosentyx ®…